Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Preliminary Results of Arm B5 of the Phase 1/2 KEYMAKER-U03B Study - Belzutifan + Lenvatinib for Pts With Advanced ccRCC After Progression on a PD-1/L1 & VEGF Inhibitor"

91 views
June 9, 2023
0 Comments
Login to view comments. Click here to Login
GU